» Articles » PMID: 7936652

R-Ras Induces Malignant, but Not Morphologic, Transformation of NIH3T3 Cells

Overview
Journal Oncogene
Date 1994 Nov 1
PMID 7936652
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Although previous studies have not identified transforming properties of the Ras-related protein R-Ras, two recent observations have prompted our further evaluation of R-Ras function. First, we observed that mutant forms of the closely related R-Ras2/TC21 protein (approximately 70% identity) exhibited the same potent transforming activity as oncogenic Ras proteins. Second, R-Ras association with Bcl-2 suggested a possible role for R-Ras in apoptotic growth control. Therefore, we have performed a detailed analysis of R-Ras transforming potential in NIH3T3 cells. Whereas expression of a mutant R-Ras protein (38V; analogous to the 12V activating Ras mutation) did not induce morphologic transformation of NIH3T3 cells, R-Ras(38V)-expressing cells proliferated in low serum, formed colonies in soft agar, and formed progressive tumors in nude mice. Like Ras-transformed cells, R-Ras(38V)-transformed cells exhibited constitutively activated mitogen activated protein kinases. Furthermore, R-Ras(38V) stimulated transcriptional activation of Ras-responsive promoter elements, and this activity (and transformation) was blocked by Raf dominant negative proteins. Finally, whereas co-expression of Bcl-2 did not cause significant alteration in wild type or mutant R-Ras transforming activity, coexpression of v-Myc and R-Ras(38V) induced a striking morphologic transformation of NIH3T3 cells. Taken together, these observations suggest that aberrant R-Ras function may stimulate malignant transformation, in the absence of morphologic transformation, via up-regulation of part of the Ras signal transduction pathway.

Citing Articles

Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation.

Czyzyk D, Yan W, Messing S, Gillette W, Tsuji T, Yamaguchi M Nat Commun. 2025; 16(1):525.

PMID: 39788953 PMC: 11718114. DOI: 10.1038/s41467-024-55766-x.


Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors.

Clavain L, Fernandez-Pisonero I, Movilla N, Lorenzo-Martin L, Nieto B, Abad A Oncogene. 2022; 42(5):389-405.

PMID: 36476833 PMC: 9883167. DOI: 10.1038/s41388-022-02563-9.


Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors.

Lai L, Fer N, Burgan W, Wall V, Xu B, Soppet D Proc Natl Acad Sci U S A. 2022; 119(5).

PMID: 35091470 PMC: 8812530. DOI: 10.1073/pnas.2113491119.


R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.

Weber S, Brossier N, Prechtl A, Barnes S, Wilson L, Brosius S Cell Commun Signal. 2021; 19(1):95.

PMID: 34530870 PMC: 8447793. DOI: 10.1186/s12964-021-00773-4.


Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains.

Michael J, Wurtzel J, Goldfinger L Oncogenesis. 2016; 5(5):e228.

PMID: 27239960 PMC: 4945753. DOI: 10.1038/oncsis.2016.36.